Decoding F508del misfolding in cystic fibrosis
- PMID: 24970227
- PMCID: PMC4101494
- DOI: 10.3390/biom4020498
Decoding F508del misfolding in cystic fibrosis
Abstract
The functional deficiency of the cystic fibrosis transmembrane conductance regulator (CFTR), a plasma membrane chloride channel, leads to the development of cystic fibrosis. The deletion of a phenylalanine at residue 508 (F508del) is the most common cause of CFTR misfolding leading to the disease. The F508del misfolding originates in the first nucleotide-binding domain (NBD1), which induces a global conformational change in CFTR through NBD1's interactions with other domains. Such global misfolding produces a mutant chloride channel that is impaired in exocytic trafficking, peripheral stability, and channel gating. The nature and atomic details of F508del misfolding have been subject to extensive research during the past decade. Current data support a central role for NBD1 in F508del misfolding and rescue. Many cis-acting NBD1 second-site mutations rescue F508del misfolding in the context of full-length CFTR. While some of these mutations appear to specifically counteract the F508del-induced misfolding, others release certain inherent conformational constraints of the human wild-type CFTR. Several small-molecule correctors were recently found to act on key interdomain interfaces of F508del CFTR. Potential rational approaches have been proposed in an attempt to develop highly effective small molecule modulators that improve the cell surface functional expression of F508del CFTR.
Figures
Similar articles
-
Integrated biophysical studies implicate partial unfolding of NBD1 of CFTR in the molecular pathogenesis of F508del cystic fibrosis.Protein Sci. 2010 Oct;19(10):1932-47. doi: 10.1002/pro.480. Protein Sci. 2010. PMID: 20687163 Free PMC article.
-
Unravelling the Regions of Mutant F508del-CFTR More Susceptible to the Action of Four Cystic Fibrosis Correctors.Int J Mol Sci. 2019 Nov 1;20(21):5463. doi: 10.3390/ijms20215463. Int J Mol Sci. 2019. PMID: 31683989 Free PMC article.
-
VX-809 corrects folding defects in cystic fibrosis transmembrane conductance regulator protein through action on membrane-spanning domain 1.Mol Biol Cell. 2013 Oct;24(19):3016-24. doi: 10.1091/mbc.E13-05-0240. Epub 2013 Aug 7. Mol Biol Cell. 2013. PMID: 23924900 Free PMC article.
-
F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review.Expert Opin Ther Pat. 2015;25(9):991-1002. doi: 10.1517/13543776.2015.1045878. Epub 2015 May 15. Expert Opin Ther Pat. 2015. PMID: 25971311 Review.
-
An overview on chemical structures as ΔF508-CFTR correctors.Eur J Med Chem. 2019 Oct 15;180:430-448. doi: 10.1016/j.ejmech.2019.07.037. Epub 2019 Jul 15. Eur J Med Chem. 2019. PMID: 31326599 Review.
Cited by
-
Cystic Fibrosis: Understanding Cystic Fibrosis Transmembrane Regulator Mutation Classification and Modulator Therapies.Adv Respir Med. 2024 Jul 20;92(4):263-277. doi: 10.3390/arm92040026. Adv Respir Med. 2024. PMID: 39051188 Free PMC article. Review.
-
The Burkholderia cenocepacia Type VI Secretion System Effector TecA Is a Virulence Factor in Mouse Models of Lung Infection.mBio. 2021 Oct 26;12(5):e0209821. doi: 10.1128/mBio.02098-21. Epub 2021 Sep 28. mBio. 2021. PMID: 34579569 Free PMC article.
-
Role of Genetic Mutations of the Na+/H+ Exchanger Isoform 1, in Human Disease and Protein Targeting and Activity.Mol Cell Biochem. 2021 Feb;476(2):1221-1232. doi: 10.1007/s11010-020-03984-4. Epub 2020 Nov 17. Mol Cell Biochem. 2021. PMID: 33201382 Review.
-
Functional Profiling of CFTR-Directed Therapeutics Using Pediatric Patient-Derived Nasal Epithelial Cell Models.Front Pediatr. 2020 Sep 4;8:536. doi: 10.3389/fped.2020.00536. eCollection 2020. Front Pediatr. 2020. PMID: 33014932 Free PMC article.
-
Systemic levels of anti-PAD4 autoantibodies correlate with airway obstruction in cystic fibrosis.J Cyst Fibros. 2019 Sep;18(5):636-645. doi: 10.1016/j.jcf.2018.12.010. Epub 2019 Jan 10. J Cyst Fibros. 2019. PMID: 30638826 Free PMC article.
References
-
- Riordan J.R., Rommens J.M., Kerem B., Alon N., Rozmahel R., Grzelczak Z., Zielenski J., Lok S., Plavsic N., Chou J.L., et al. Identification of the cystic fibrosis gene: Cloning and characterization of complementary DNA. Science. 1989;245:1066–1073. - PubMed
-
- Cheng S.H., Gregory R.J., Marshall J., Paul S., Souza D.W., White G.A., O’Riordan C.R., Smith A.E. Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. Cell. 1990;63:827–834. - PubMed
-
- Denning G.M., Anderson M.P., Amara J.F., Marshall J., Smith A.E., Welsh M.J. Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive. Nature. 1992;358:761–764. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
